Skip to content Skip to navigation

Medication Treatments

Brightside Clinic hires medical director

March 20, 2017  |  Gary A. Enos, Editor
news
David Kushner, DO, FACP, has been named medical director at Brightside Clinic, the buprenorphine treatment organization with offices in two Illinois communities.

Report: Risk of long-term opioid use increases in initial week of treatment

March 17, 2017  |  Gary A. Enos, Editor
article
Data released this week by the Centers for Disease Control and Prevention (CDC) make a case for significant limits on initial prescriptions of opioids.

Study highlights threat of dual use of buprenorphine and other opioids

March 7, 2017  |  Rachael Zimlich, RN, Contributing Writer
article
Research using a pharmacy database leads to striking findings about the prevalence of other opioid use during and after buprenorphine treatment.

Readers open to idea of marijuana-inclusive treatment

February 28, 2017  |  Tom Valentino, Senior Editor
blog
Our story last week on the use of marijuana in addiction treatment has generated a lot of reader feedback, with many commenters willing to consider the practice.

Treatment that includes marijuana use ignites debate

February 21, 2017  |  Tom Valentino, Senior Editor
article
High Sobriety in West Los Angeles is the latest example of treatment centers using marijuana as part of treatment for addiction to alcohol and other drugs, a highly polarizing practice.

Researchers quantify benefit of medication intervention in emergency care

February 14, 2017  |  Gary A. Enos, Editor
news
New research suggests that opioid-addicted individuals who receive buprenorphine during an emergency medical visit show better treatment engagement for two months following the intervention.

New Jersey opioid law mandates prescriber discussions with young patients

February 8, 2017  |  Gary A. Enos, Editor
news
Advocates believe a newly adopted New Jersey law designed to educate youths and their families about the dangers of opioid addiction could add momentum for other opioid-focused legislation.

ASAM partners on training of NPs, PAs in buprenorphine prescribing

January 17, 2017  |  Gary A. Enos, Editor
news
The American Society of Addiction Medicine (ASAM) has partnered with associations representing nurse practitioners and physician assistants to offer training courses for these professionals in buprenorphine prescribing.

Five facts about new versions of buprenorphine

January 13, 2017  |  Gary A. Enos, Editor
article
Injectable and implant versions of buprenorphine are seen as potentially significant breakthroughs in improving medication adherence and reducing diversion.

FDA will remove warning language on drugs for smoking cessation

December 19, 2016  |  Gary A. Enos, Editor
news
Results of a clinical trial have convinced the Food and Drug Administration (FDA) that the risk of neuropsychiatric adverse events from the brand-name drugs Chantix and Zyban is lower than originally believed.

Settlement over prescribing practices puts spotlight on buprenorphine clinics

December 2, 2016  |  Gary A. Enos, Editor
article
A well-regarded chain of buprenorphine treatment operations has agreed to pay a civil settlement in a case that in part speaks to concerns about the mix of services in medication-assisted treatment facilities.

App from SAMHSA guides medication treatment for opioid dependence

December 1, 2016  |  Gary A. Enos, Editor
news
The new MATx app is designed to share treatment strategies and other resources for the use of medications to treat opioid use disorders.

Pages

Subscribe to Medication Treatments